Medtronic (Minneapolis) has hit a huge bump in the road in its bid to get its Amplify rhBMP-2 matrix onto the U.S. market. The med-tech giant's plans for the bone graft to be approved were stalled when the FDA sent it a letter saying that it wouldn't be able to approve the application without additional information from the firm. (Medical Device Daily) Read More
